Multiplikator forward rega marang pendapatan OS Therapies, Inc. (OSTX)
OS Therapies Incorporated (OSTX) enjoys deep trust from pediatric oncologists and specialized funds as a bold scientific visionary. The business's forward P/S helps track the dynamics of this sector, and the metric has currently reached the level of . Growth is driven by FDA Fast Track designations and M&A prospects, while the strategy relies on a listeria platform to combat solid tumors.
OSTX (OS Therapies, Inc.): rincian analitis lan laporan miturut indikator
- rega pasar lan target rega analis:
- rincian kapitalisasi pasar:
- rincian valuasi buku bisnis:
- informasi babagan utang lan solvabilitas:
Total Utang marang Modal OS Therapies Incorporated|OSTX - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas OS Therapies Incorporated|OSTX - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku OS Therapies, Inc.|OSTX - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan OS Therapies|Rasio cepet ostherapies.com
- indikator pendapatan resik lan kelipatan nilai:
OSTX - Asil keuangan resik|Proyeksi bathi mangsa ngarep OS Therapies Incorporated|OSTX - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep OS Therapies Inc|OSTX - Kapitalisasi marang bathi resik kanthi nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan OS Therapies, Inc.|OSTX - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) OS Therapies|OSTX - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan ostherapies.com|OSTX - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep OS Therapies Incorporated
- rincian pendapatan lan dodolan emiten:
Ringkesan analisis perusahaan:OS Therapies OSTX
The forward P/S ratio correlates the current market value of OS Therapies Incorporated (OSTX) with revenue forecasts, allowing for an assessment of the premium paid for future cash flows. The trend of the expected revenue multiple on GURU.Markets reflects market confidence in the success of the company's diversified oncology drug portfolio, where the distribution of risks across different trial stages directly impacts the asset's investment attractiveness.
Pesaing OS Therapies Incorporated
Rasio rega marang prakiraan pendapatan BeiGene ONC|Rasio kapitalisasi marang dodolan sing dikarepake Halozyme Therapeutics, Inc. (HALO)|RVMD: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan AAPG (Ascentage Pharma Corp)|CGON (CG Oncology, Inc.) - Multiplikator forward rega marang pendapatan|URGN: Rasio rega marang pendapatan sing dikarepake|BCAX (Bicara Therapeutics) - Multiplikator Forward P/S|PSNL: Rega forward marang dodolan|Multiplikator Forward P/S ERAS|DCTH - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Y-mAbs Therapeutics YMAB|Rega forward marang dodolan AURA|Candel - Multiplikator Forward P/S|ARAY - Multiplikator Forward P/S|sellaslifesciences.com (SLS) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan ACTU (Actuate Therapeutics Inc)|CTOR (Citius Oncology, Inc.) - Multiplikator Forward P/S|TuHURA (HURA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S TARA|FATE - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Aadi Bioscience WHWK|Rasio kapitalisasi marang dodolan sing dikarepake TScan Therapeutics Inc (TCRX)|CSBR: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan XBIT (XBiotech Inc.)|CVM: Multiplikator Forward P/S|RADX - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Artiva Biotherapeutics Inc.|Kapitalisasi marang prakiraan pendapatan ANL (Adlai Nortye Limited)|Multiplikator Forward P/S VERU|Multiplikator forward rega marang pendapatan tempesttx.com TPST|Rasio rega marang prakiraan pendapatan Xilio Therapeutics XLO|Renovaro Biosciences (RENB) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|MURA - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan KAPA (Kairos Pharma Ltd)|onkuretherapeutics.com (OKUR) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan GDTC (CytoMed Therapeutics Limited)|Rasio rega marang prakiraan pendapatan Curis Inc.|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Apollomics Corp APLM|Rasio rega marang prakiraan pendapatan Tharimmune Corp (THAR)|ADVB (advanbiomed.com) - Rega forward marang dodolan|Multiplikator Forward P/S GNPX (Genprex, Inc.)|Multiplikator Forward P/S Calidi Biotherapeutics Inc. CLDI|SBFM: Multiplikator forward rega marang pendapatan|Xenetic Biosciences - Rasio rega marang pendapatan sing dikarepake|SLRX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Kitov Pharma (PPBT)|AONC (American Oncology Network Inc) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan BGNE (beigene.com)|Rasio rega marang prakiraan pendapatan Checkpoint Therapeutics, Inc. (CKPT)|ELEV - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan iCAD ICAD|Rasio kapitalisasi marang dodolan sing dikarepake Ikena Oncology Inc. (IKNA)|NTBL: Multiplikator forward rega marang pendapatan|Viracta Therapeutics - Rasio rega marang pendapatan sing dikarepake|MOR (MorphoSys) - Multiplikator forward rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan NAYA|AAPGV (Ascentage Pharma Group Ltd) - Multiplikator Forward P/S
